ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) has officially announced the full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery in Nashville. This groundbreaking technology is set to revolutionize the field of neurosurgery and provide new treatment options for patients.

According to Dr. Kim Burchiel, Professor of Neurological Surgery at the Oregon Health & Science University, “Deep Brain Stimulation (DBS) has been proven to be a safe and effective strategy to manage patients with medically intractable Parkinson’s Disease, Essential Tremor, and Dystonia.” The SmartFrame OR platform is expected to make DBS procedures more accessible to a wider range of patients, ultimately improving outcomes and patient acceptance.

Dr. Andrew Conner, Assistant Professor of Neurosurgery at Oklahoma University, praised ClearPoint Neuro’s new SmartFrame OR solution for its precision and efficiency in stereotactic procedures. The technology has already made a significant impact on DBS practices since its release.

ClearPoint Neuro’s President and CEO, Joe Burnett, expressed excitement about the company’s innovative advancements in neurosurgery. The new SmartFrame OR and ClearPoint Prism Neuro Laser Therapy System are just a few examples of the cutting-edge technologies being showcased at the conference.

The SmartFrame OR and ClearPoint Prism Neuro Laser Therapy System will be highlighted at the conference, offering attendees a firsthand look at the future of neurosurgical navigation and treatment options.

ClearPoint Neuro continues to lead the way in device, cell, and gene therapy-enabled solutions for precise navigation to the brain and spine. With a focus on innovation and patient care, the company is dedicated to providing the best possible outcomes for patients worldwide.

For more information about ClearPoint Neuro and their groundbreaking technologies, please visit

Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
Investor Relations:
Danilo D’Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3